Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX-1431 in Adults with Tourette Syndrome
NCT03625453Phase 2Completed
- Sponsor
- Abide Therapeutics
- Start
- Oct 2018
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in Tourette syndrome (TS) and chronic motor tic disorder comparing ABX-1431 with Placebo (2 arms). Primary endpoint: Yale Global Tic Severity Scale - Total Tic Score at Day 56. Started Oct 2018; status: completed.
02
Drugs
ABX-1431
03
Conditions
Tourette syndrome (TS)chronic motor tic disorder
Beyond the preview
Go deeper on NCT03625453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03625453.